Select Page

Source: IBEF

“Bharat Biotech’s Covid-19 vaccine, Covaxin, is now under phase-3 trials, Mr. Krishna Ella, Bharat Biotech’s Chairman and Managing Director, said on Monday.

Speaking at an Indian School of Business programme, Mr. Ella said the company is also focused on another Covid-19 vaccine that would be in the form of nasal drops and should be ready by next year.

“”We collaborated with ICMR for the COVID-19 vaccine when it reached phase 3 trials,”” he said.

Mr. Krishna Ella said that Bharat Biotech is the world’s only vaccine company with a manufacturing facility for BSL3 (Biosafety level 3).

The vaccine manufacturer confirmed last month that it had successfully completed an interim review of the vaccine’s Phase I and II trials and is initiating Phase III trials for 26,000 participants.

In collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV), Covaxinis is being developed by BharatBiotech.

On October 2, the city-based vaccine manufacturer requested permission from the Drug Controller General of India (DCGI) to perform a phase 3 randomised double-blind placebo-controlled multicentre trial of its COVID-19 vaccine, sources said.

“”We are working on another nasal drop vaccine. My feeling is that it will reach the population by next year,”” Mr. Ella said.

BharatBiotechin September said it had entered into a licencing agreement for a novel “”chimpanzee adenovirus”” (Chimpanzee adenovirus), single dose intranasal vaccine for COVID-19, with the Washington University School of Medicine in St. Louis.”